Gilead to Acquire Arcellx for $7.8B, Bolstering CAR-T Pipeline
Event summary
- Gilead Sciences to acquire Arcellx for $7.8B, including a $5 per share contingent value right tied to anito-cel sales.
- Arcellx’s lead candidate, anito-cel, a BCMA-directed CAR-T therapy for multiple myeloma, has a PDUFA action date of December 23, 2026.
- Gilead currently owns 11.5% of Arcellx’s outstanding common stock.
- Transaction expected to close in Q2 2026, subject to regulatory approvals and shareholder tender.
The big picture
Gilead’s acquisition of Arcellx underscores its strategic push into next-generation cell therapies, particularly in oncology. The deal follows Gilead’s $32B investment in 2025 to strengthen its U.S. footprint and underscores the industry’s shift toward targeted immunotherapies. The transaction is expected to be accretive to earnings per share post-2028, contingent on anito-cel’s commercial success.
What we're watching
- Regulatory Approval
- Whether anito-cel secures FDA approval by the December 23, 2026 PDUFA date, which is critical for the transaction’s earnings accretion starting in 2028.
- Integration Challenges
- How Gilead will integrate Arcellx’s D-Domain CAR technology platform into its existing oncology portfolio, particularly in leveraging the BCMA binder for in vivo cell therapy.
- Market Competition
- The pace at which Gilead can differentiate anito-cel in the competitive multiple myeloma treatment landscape, especially for earlier lines of therapy.
Related topics